A Message from Veracyte’s CEO About COVID-19     Learn More
A Message from Veracyte’s CEO About COVID-19     Learn More
Why did I seek more?
Knowing that there was a test that could help resolve an indeterminate diagnosis meant the world to me. I would do just about anything to avoid surgery and I trusted my doctor.
Real People
Knowing
Real Answers.
KAREN MELMED
Afirma Patient
This is the Age of Evidence.
Where a new definition of diagnostic truth is changing patient care as we know it. Where physicians and patients can now benefit from the evolution of healthcare and know, by design, the answers they seek.

Veracyte gives patients a clearer path for the future.

We are leading in the Age of Evidence.

LEARN MORE >
our impact
LATEST NEWS
New data published in The Lancet Respiratory Medicine show that the Envisia Genomic Classifier improves diagnosis of IPF
learn more >
LATEST NEWS
Veracyte Launches Next-Generation Percepta® Genomic Sequencing Classifier for improved lung cancer diagnosis
learn more >
WATCH
Bonnie Anderson, Veracyte CEO interview with Bill Vick/PF Warriors about the Envisia Genomic Classifier and plans to transform IPF/ILD diagnosis

WATCH NOW >


latest news
news and updates
COVID-19 is Driving a Shift in How We Value Diagnostic Tests
Timmerman Report
Aug 6, 2020
Oncology Beyond COVID-19
The MedTech Strategist
Jun 22, 2020
Dr. Giulia C. Kennedy, Veracyte’s CSO and CMO, Named One of the “2020 Most Influential Women in Bay Area Business”
San Francisco Business Times
Jun 4, 2020